Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : AFT Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Hyloris Announces Commercial Partnership for Maxigesic IV in 9 European Countries
Details : Maxigesic (paracetamol) IV is a novel, dual mode-of-action, non-opioid pain treatment delivered through intravenous (IV) infusion for use post-operatively in hospitals or when patients cannot take medicine orally.
Product Name : Maxigesic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 24, 2023
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : AFT Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Aztreonam
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Recipient : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 26, 2010
Lead Product(s) : Aztreonam
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Recipient : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
